

Hutchison Whampoa Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 013)

OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of the announcement, the Directors of Hutchison Whampoa Limited are:

Executive Directors:

Mr. LI Ka-shing (*Chairman*)
Mr. LI Tzar Kuoi, Victor (*Deputy Chairman*)
Mr. FOK Kin-ning, Canning
Mrs. CHOW WOO Mo Fong, Susan
Mr. Frank John SIXT
Mr. LAI Kai Ming, Dominic
Mr. KAM Hing Lam

Non-executive Directors:

Mr. George Colin MAGNUS
Mr. William SHURNIAK

Independent Non-executive Directors:

The Hon. Sir Michael David KADOORIE
Mr. Holger KLUGE
Mr. William Elkin MOCATTA
*(Alternate to The Hon. Sir Michael
David Kadoorie)*
Mr. OR Ching Fai, Raymond
Mr. WONG Chung Hin

Hong Kong, 22 May 2007



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)**

Director's Shareholding

London: Tuesday, 22 May 2007: Chi-Med was informed on 18 May 2007 that Mr. Christian Hogg, Executive Director and Chief Executive Officer of Chi-Med, purchased 70,000 ordinary shares of US\$1 each in Chi-Med (the "Shares") at a price of 153p each on 18 May 2007.

Following this purchase, Mr. Hogg is beneficially interested in 170,000 Shares and vested option to subscribe for up to 384,091 Shares, representing approximately 1.1% of the current issued share capital of Chi-Med.

Ends

Enquiries

Chi-Med

Telephone: +852 2121 8200

Christian Hogg, CEO

Citigate Dewe Rogerson

Telephone: +44 (0) 20 7638 9571

Anthony Carlisle
Yvonne Alexander

Mobile: +44 (0) 7973 611 888
Mobile: +44 (0) 7866 610 682

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.